The price of ITRM is predicted to go up 1.69%, based on the high correlation periods with BANR. The similarity of these two price pattern on the periods is 93.06%.

ITRM

BANR

Up: 1.69%Similarity: 93.06%

ITRM Revenue Forecast

ITRM EPS Forecast

ITRM FAQs

What is bull’s view on ITRM?

Iterum Therapeutics (ITRM) has recently regained Nasdaq compliance and received FDA approval for Orlynvah, its first approved product for UTIs. Despite these milestones, the stock closed at $1.59 on January 31, 2025, with limited upward momentum. Bulls may argue that the FDA approval positions ITRM for long-term growth, potentially driving the stock above $2.00 if commercialization efforts succeed.

What is bear's view on ITRM?

ITRM stock is currently trading at $1.59, reflecting a bearish sentiment due to weak market confidence despite FDA approval for Orlynvah. The stock's inability to sustain gains post-approval and its recent 1.2% decline in premarket trading indicate limited investor enthusiasm. Additionally, its low trading volume and lack of significant catalysts suggest further downside risk.